OncLive On Air®
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA, discuss diagnostic and treatment strategies for patients with MET-altered non–small cell lung cancer.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from AbbVie, Inc.
Moderator:
Jonathan Goldman, MD
Professor of Medicine, Division of Hematology/Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Early Drug Development
University of California, Los Angeles
Santa Monica, CA
Faculty:
Sanja Dacic, MD, PhD
Professor of Pathology
Vice Chair and Director of Anatomic Pathology
Director, Thoracic Pathology
Department of Pathology
Yale School of Medicine
New Haven, CT
Deborah Doroshow, MD, PhD
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Anne S. Tsao, MD, MBA
Vice President, Academic Affairs
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
The University of Texas MD Anderson Cancer Center
Houston, TX
This podcast, including the narration, was produced by the PER® editorial staff based on an online activity conducted with these faculty members. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including a detailed discussion of MET alteration detection, go to
Release Date
August 24, 2026
Expiration Date
August 24, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for educational purposes only. It is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
